Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010

Sanz-Granda, Á; Hidalgo, Álvaro; Llano, Juan E. del; Rovira, Joan

doi:10.1007/s12094-012-0934-8

Cited by 4 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with these findings, another review of 242 cancer-related CUAs published in different parts of the world, through 2007, showed that the most frequent cancers studied were breast cancer (36% of studies), colorectal cancer (12%), and hematologic cancers (10%) ( 70 , 71 ). In Spain, 13.0% of economic evaluations, published between 1990 and 2009, referred to cancer-related processes ( 72 ), and the disease most frequently evaluated was non-small cell lung cancer (31 %) ( 73 ).…”

Section: Discussionmentioning

confidence: 99%

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Campolina

et al. 2018

Front. Public Health

View full text Add to dashboard Cite

Background: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied. Objective: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context.Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013).Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO).Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.

show abstract

Section: Discussionmentioning

confidence: 99%

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Campolina

et al. 2018

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…15,16 The debates on methodological aspects and practical application of EE are similar to international ones [17][18][19] and with common emphasis on the need to improve the quality and credibility of EE. [20][21][22][23][24] This activity has been carried out by agents from both the public and private sectors. On the public side, the 8 HTA agencies in Spain have been coordinated through the Spanish Network of HTA Agencies (RedETS) since 2012.…”

Section: Development Of the Legal And Policy Framework For The Use Ofmentioning

confidence: 99%

Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?

et al. 2020

View full text Add to dashboard Cite

Background: The economic evaluation of healthcare technologies has become in many countries a basic tool for reimbursement, pricing and purchasing decisions. Objective: The objective of this article is to examine the institutional, legal, and political factors that have impeded the application of economic evaluation and the criterion of efficiency in the process of pricing and reimbursement of new medicines in Spain. Methods: Narrative description of the current institutional framework for the use of economic evaluation in pricing and reimbursement in Spain, legal and policy framework in the field of evaluation of new medicines, and stakeholder initiatives and policies related to the use of economic evaluation outside of the pricing and reimbursement process. Results: Spain has an institutional framework created and established over the last years that could have facilitated a formal use of economic evaluation in the process of pricing and reimbursement. Nevertheless, the real use of economic evaluation at the central or regional level is still unknown, although application of the efficiency criterion, linking to cost-effectiveness, has been clearly required by Spanish laws and regulations at the national level. We highlight a certain degree of moral hazard from the central government that is not directly responsible for the budget impact of reimbursement and pricing decisions. There are currently a number of ongoing initiatives in the field of economic evaluation by various agents, but they remain uncoordinated. Conclusions: Poor governance at the highest level of decision making is the main reason for the lack of interest in economic evaluation. A profound political change, supported by transparency and accountability, is required before the criterion of efficiency can be fully considered in the process of pricing and reimbursement of new medicines in Spain.

show abstract

“…En este ámbito, los de tipo coste-utilidad están adquiriendo cada día mayor relevancia al incorporar la dimensión de la calidad de vida, unida al hard endpoint más importante, la muerte. Así, en la actualidad se publican con frecuencia revisiones sistemáticas de las evaluaciones económicas efectuadas en una gran variedad de tratamientos, como cáncer de pulmón de células no pequeñas (35) , esquizofrenia (36) , Alzheimer (37) , tuberculosis resistente (38) , púrpura trombocitopénica (39) , o incluso, análisis de las evaluaciones económicas efectuadas en nuestro país, durante los últimos años, en campos más amplios como el cáncer (40) , las vacunas (41) o los trastornos mentales (42) .…”

Section: Eficiencia De Los Tratamientos Farmacológicosunclassified